Horsham, PA (PRWEB) March 28, 2012
DIA, along with industry experts and regulators, will convene to improve safety analysis during drug development, as well as analyze and mitigate potential risks and explore new solutions and approaches to developing safe and effective medications, including those to treat Type 2 Diabetes Mellitus.
Cardiovascular Safety and State-of-the-art Development Issues: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity will be held April 17-18 in Washington, DC.
The conference will include plenary sessions and two concurrent tracks: one to address Diabetes-related topics and to address Cardiovascular Safety-related topics. Session topics will include:
“Attendees participate in debate-style presentations and hear commentary from international industry, academic, and regulatory speakers to help them optimize their cardiovascular safety assessment, as well as improve the development of medications to treat Type 2 Diabetes Mellitus and other diseases,” says Program Chairperson Philip T. Sager, MD, FACC, FAHA. “This is our goal for this meeting.”
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India and Beijing, China. http://www.diahome.org.
Contacts: Joe Krasowski